Cat. No. 3203
Chemical Name: (9β,13α,14β,20α)-3-Hydroxy-9,13-dimethy
Biological ActivityAntioxidant and anti-inflammatory agent. Potently inhibits lipid peroxidation in mitochondria and inhibits TNF-α-induced NFκB activation. Also shown to inhibit topoisomerase II activity in vitro (IC50 = 7.41 μM).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Sethi et al (2007) Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-κB-regulated gene products and TAK1-mediated NF-κB activation. Blood 109 2727. PMID: 17110449.
Nagase et al (2003) Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci.Biotechnol.Biochem. 67 1883. PMID: 14519971.
Sassa et al (1990) The triterpene celastrol as a very potent inhibitor of lipid peroxidation in mitochondria. Biochem.Biophys.Res.Comms. 172 890.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Celastrol include:
Zwicker et al (2015) Interleukin 34: a new modulator of human and experimental inflammatory bowel disease. Clin Sci (Lond) 129 281. PMID: 25896238.
Do you know of a great paper that uses Celastrol from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Celastrol, supplier, inhibitors, inhibits, TNF-α, TNF-alpha-induced, NF-κB, NF-kappaB, NF-kB, activation, Antioxidant, anti-inflammatory, Topoisomerase, II, Nuclear, Factor, Kappa, B, Cytokine, Signaling, Signalling, Transcription, Factors, DNA, Isomerases, Tocris Bioscience, NF-κB and IκB Inhibitor products
Find multiple products by catalog number
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.